Completed PHASE3 INTERVENTIONAL NCT00232661

PROACT - Pre-Operative Arimidex Compared To Tamoxifen

A Randomised, Double-blind, Study Comparing ARIMIDEX™ With NOLVADEX™ as Neo-adjuvant and Adjuvant Treatment in Post-menopausal Women With Large Operable (T2 (≥3cm), T3, N0-2, M0) or Potentially-operable, Locally Advanced (T4b, N0-2, M0), ER+ and/or PR+ Breast Cancer.

Sponsor: AstraZeneca

Conditions Breast Cancer

Interventions ARIMIDEX (anastrazole) NOLVADEX (tamoxifen)

Updated 7 times since 2017 Last updated: Feb 2, 2010 Started: Aug 31, 2000 Primary completion: Jan 31, 2003 Completion: Dec 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00232661, this PHASE3 trial focuses on Breast Cancer and remains completed. Sponsored by AstraZeneca, it has been updated 7 times since 2000, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Aug 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Amagasaki, Japan , Antwerp, Belgium , Austin, United States , Avignon, France , Baton Rouge, United States , Bologna, Italy , Brno, Czechia , Budapest, Hungary , Cagliari, Italy and 67 more locations